Chester County News and Community Website
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported full results from a Phase 1a clinical trial of its ATI-052 antibody and outlined plans to advance multiple programs, including selecting …
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline Read More
WASHINGTON, D.C. — Federal regulators are moving to speed up drug development by launching real-time clinical trials that allow safety data and results to be reviewed as studies are underway …
FDA Pushes Faster Drug Approvals With Real-Time Trials Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 …
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference Read More
HARRISBURG, PA — Pennsylvania researchers can now apply for $5 million in state funding aimed at advancing treatments and potential cures for neurodegenerative diseases affecting hundreds of thousands of residents.
PA Opens $5M Grant Push to Fight Alzheimer’s, ALS, Parkinson’s Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for …
Annovis Bio Highlights Buntanetap Development in Published Article Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the publication of a review article in the Journal of Vascular Anomalies examining clinical differences and treatment approaches for microcystic and …
Palvella Publishes Review on Lymphatic Malformations in Medical Journal Read More WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy …
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group …
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy Read More